Expertise in
9
conditions

Dr. Juliet N. Barker

Hematology | Oncology
Bone Marrow Transplant And Cell Therapy Program
520 E 70th St # 3, 
New York, NY 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
31 Years of Experience
Expertise in
9
conditions
Bone Marrow Transplant And Cell Therapy Program
520 E 70th St # 3, 
New York, NY 

Overview

Juliet Barker is a Hematologist and an Oncologist practicing medicine in New York, New York. She has been practicing medicine for over 31 years.

Dr. Barker is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Graft.

She is actively involved in clinical research, co-authoring 127 peer reviewed articles and participating in 7 clinical trials. Dr. Barker is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in NY

Hospital Affiliations

New York-Presbyterian Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 2 Less Insurance Carriers -

Locations

Bone Marrow Transplant and Cell Therapy Program
520 E 70th St # 3, New York, NY 10021

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: July 06, 2026
Intervention Type: Drug
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
Enrollment Status: Recruiting
Publish Date: April 13, 2026
Intervention Type: Biological
Study Phase: Phase 2
Pilot Study: Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells (Dilanubicel) in the Setting of Single Cord Blood Transplantation for Patients With Hematologic Malignancies
Pilot Study: Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells (Dilanubicel) in the Setting of Single Cord Blood Transplantation for Patients With Hematologic Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Drug, Radiation, Procedure, Other, Biological
Study Drugs: Dilanubicel, Cyclophosphamide, Fludarabine, Thiotepa
Study Phase: Phase 2
Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells to Facilitate the Engraftment of a Single CCR5Δ32 Homozygous or Heterozygous Cord Blood Unit in Patients With HIV and Hematological Malignancies
Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells to Facilitate the Engraftment of a Single CCR5Δ32 Homozygous or Heterozygous Cord Blood Unit in Patients With HIV and Hematological Malignancies
Enrollment Status: Terminated
Publish Date: January 01, 2025
Intervention Type: Drug, Radiation, Procedure, Biological
Study Drugs: Fludarabine, Cyclophosphamide, Thiotepa
Study Phase: Phase 2
A Reduced Intensity Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.
A Reduced Intensity Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.
Enrollment Status: Completed
Publish Date: December 08, 2022
Intervention Type: Drug
Study Phase: Phase 2
Myeloablative Unrelated Donor Cord Blood Transplantation With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for Patients With High Risk Hematological Malignancies
Myeloablative Unrelated Donor Cord Blood Transplantation With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for Patients With High Risk Hematological Malignancies
Enrollment Status: Completed
Publish Date: August 05, 2022
Intervention Type: Device, Biological
Study Phase: Phase 2
A Phase 1 Open-Label, Multi-Center Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord
A Phase 1 Open-Label, Multi-Center Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord
Enrollment Status: Completed
Publish Date: May 31, 2022
Intervention Type: Biological
Study Drugs: Unmanipulated Umbilical Cord Blood, AB-110
Study Phase: Phase 1
View 5 Less Clinical Trials

127 Total Publications

Optimizing methods to detect colonization with fluoroquinolone-resistant viridans group streptococci prior to hematopoietic cell transplantation.
Optimizing methods to detect colonization with fluoroquinolone-resistant viridans group streptococci prior to hematopoietic cell transplantation.
Journal: Journal of clinical microbiology
Published: August 21, 2026
Similar Doctors
Expertise in
34
conditions
Dr. Steven M. Horwitz
Hematology | Oncology
Expertise in
34
conditions
Dr. Steven M. Horwitz
Hematology | Oncology
Referral may be required

David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center

530 E 74th St, 
New York, NY 
 (0.4 miles away)
646-535-8986
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Steven Horwitz is a Hematologist and an Oncologist practicing medicine in New York, New York. Dr. Horwitz is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Horwitz is currently accepting new patients.

Expertise in
27
conditions
Dr. Gilles A. Salles
Hematology | Oncology
Expertise in
27
conditions
Dr. Gilles A. Salles
Hematology | Oncology
Referral may be required

David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center

530 E 74th St, 
New York, NY 
 (0.4 miles away)
929-298-9410
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gilles Salles is a Hematologist and an Oncologist practicing medicine in New York, New York. Dr. Salles is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Bone Marrow Transplant, and Splenectomy. Dr. Salles is currently accepting new patients.

Expertise in
31
conditions
Dr. Alison J. Moskowitz
Hematology | Oncology
Expertise in
31
conditions
Dr. Alison J. Moskowitz
Hematology | Oncology
Referral may be required

David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center

530 E 74th St, 
New York, NY 
 (0.4 miles away)
332-456-0508
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alison Moskowitz is a Hematologist and an Oncologist practicing medicine in New York, New York. Dr. Moskowitz is highly rated in 31 conditions, according to our data. Her clinical expertise encompasses Hodgkin Lymphoma, T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Moskowitz is currently accepting new patients.

Frequently Asked Questions about Dr. Juliet N. Barker

How do I make an appointment with Dr. Juliet N. Barker?

You can book an appointment with Dr. Juliet N. Barker by calling their office at 347-380-5531. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Juliet N. Barker a top-rated expert for Bone Marrow Transplant?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Juliet N. Barker is classified as an Distinguished expert for Bone Marrow Transplant, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Juliet N. Barker specialize in?

While Dr. Juliet N. Barker is a Hematology, they have specific expertise in Bone Marrow Transplant, Acute Myeloid Leukemia (AML), and Acute Lymphoblastic Leukemia (ALL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Juliet N. Barker participate in research or clinical trials?

Yes. Dr. Juliet N. Barker has published 127 articles and abstracts on conditions like Bone Marrow Transplant. You can view a list of Dr. Juliet N. Barker's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Juliet N. Barker accept my insurance?

Dr. Juliet N. Barker accepts most major insurance plans, including Aetna and Cigna. We recommend calling the office directly at 347-380-5531 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Barker's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 23 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile